

Click for full [Prescribing Information](#) for
Bupivacaine Spinal (bupivacaine hydrochloride in dextrose injection, USP)

Pfizer Inc.
275 North Field Drive
Lake Forest, IL 60045



September 01, 2026

**Return and Disposal Guidance for
Bupivacaine Spinal (bupivacaine hydrochloride in dextrose injection, USP)
with Emergency Extended Use Dating**

Dear Valued Customer,

In April of this year, Pfizer received approval from the U.S. Food and Drug Administration (FDA) of our emergency request to extend the use date for several lots of **Bupivacaine Spinal (bupivacaine hydrochloride in dextrose injection, USP)** to mitigate shortages of this critical product. Impacted lot numbers and extended use dates are outlined in the tables at the end of this letter.

As a follow up to the [April 2026 communication](#), Pfizer is providing additional guidance on how to properly return or destroy affected product if replacement product becomes available during the extended use period. As previously communicated, customers are expected to replace and properly dispose of affected product as soon as possible.

Please contact Pfizer Customer Service to request one of the following:

- **Product return:** Pfizer will provide a prepaid return label or arrange for pickup for the product to be returned to Inmar for destruction. Once product is received by Inmar, the return will be processed and credit will be issued. Credit processing may take up to four weeks.
- **On-site destruction:** If you are unable to return the product and have a compliant way for destroying it on site, contact Pfizer Customer Service to obtain a Certificate of Destruction Form. Once the completed and signed form is received, credit will be issued.

For either option, please provide:

- Product/NDC Number
- Lot Number(s)
- Quantity (Unit of Sale)

If you have any questions, please call our Customer Service Department at 1-844-646-4398.

Thank you,

Kim Rouse Wing

Director, U.S. Marketing, Anesthesia

Global Hospital & Biosimilars, U.S. Commercial

Emergency Extended Use Dating: Bupivacaine Spinal (bupivacaine hydrochloride in dextrose injection, USP)

Unit of Sale NDC	Unit of Use NDC	Product Description	Lot Number	Labeled Expiration Date	Extended Use Date
00409- 3613-01	00409-3613-11	Bupivacaine Spinal (bupivacaine HCl 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25% Injection, USP)	LD2831 LD2832 LD2855 LE2563	02/28/26	02/28/27

© 2026 Pfizer Inc. All rights reserved. September 2026

